Cyclogenix Enters Research Collaboration with Wyeth Pharmaceuticals (New Jersey) and Queensland’s IMBcom

ABERDEEN, Scotland--(BUSINESS WIRE)--Cyclogenix Ltd today announced that it has entered into license and research agreements with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE) and IMBcom, The University of Queensland’s (UQ) company for commercializing technology from the Institute for Molecular Bioscience (IMB).

Back to news